---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000012"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:51:34.567391+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences reports FY 2023 net loss $102.1M, cash $372.4M; clinical updates

## Summary
- Net loss $102.1M in FY 2023 vs $99.4M in FY 2022; R&D expenses rose to $112.1M.
- Cash, equivalents, and marketable securities $372.4M at Dec 31, 2023, up from $317.0M; expected to fund operations into Q1 2026.
- CB-010: 30th patient dosed in ANTLER dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024.
- CB-012: First patient dosed in AMpLify Phase 1 trial for r/r AML.
- CB-020 preclinical anti-ROR1 CAR-NK program paused; CB-011 enrollment continues at dose level 3.

## SEC filing metadata
- accession: 0001619856-24-000012
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000012/0001619856-24-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000012/crbu-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000012
- JSON: https://secwatch.observer/filing/0001619856-24-000012.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000012.txt

## Key facts
- Earnings Releases
  Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 11, 2024, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000012/0001619856-24-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.